Results 141 to 150 of about 2,337,951 (308)

Focal HIFU for prostate cancer

open access: yes, 2012
We read with interest the report by Hashim Ahmed and colleagues 1 claiming low rates of side-effects and promising results of focal high-intensity focused ultrasound (HIFU) for localised prostate cancer.
J. W. Leer   +6 more
core   +1 more source

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

open access: yesAdvanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li   +13 more
wiley   +1 more source

Multifunctional Nanovaccine‐Radiotherapy Synergy Drives Anti‐Tumor Immunity via Multi‐Cascade Cell Death for Pancreatic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Machine‐learning‐driven transcriptomic analysis identifies FSTL3 as a key tumor‐microenvironment regulator in desmoplastic pancreatic adenocarcinoma. A cRGD‐modified liposome co‐loading gemcitabine and siFSTL3 serves as an irradiation‐triggered in situ nanovaccine. It synergizes with radiotherapy to induce ferroptosis and immunogenic cell death through
Chengyi Huang   +11 more
wiley   +1 more source

A radiation oncologist's story: high tech meets high touch

open access: yes, 2014
Personal reflection on the interplay between radiation oncology, which has long been on the leading edge of technological advances in treatment planning and delivery systems, and the personal side of medicine, often known as high ...
Pieters, Richard S.
core   +1 more source

TP53 Loss Elevates NF‐κB‐IFN‐β‐MHC‐Ia Signaling to Promote NK Cell Resistance in Osteosarcoma

open access: yesAdvanced Science, EarlyView.
TP53 loss in a transforming or osteosarcoma cell promotes cytosolic DNA accumulation, activating NF‐κB‐dependent IFN‐β production. Autocrine IFN‐β signaling increases cell‐surface HLA‐Ia expression, strengthens inhibitory KIR signaling in natural killer cells, and thereby enables the affected cell to evade NK cell‐mediated cytotoxicity.
Guihui Qin   +9 more
wiley   +1 more source

Pan-Canadian Survey of Radiation Oncology Professional Involvement in Global Oncology Initiatives in Low- and Middle-Income Countries

open access: yesJCO Global Oncology
PURPOSECanadian radiation oncology professionals have a strong history of involvement in global oncology initiatives worldwide. This pan-Canadian survey-based study was conducted to determine the current level of engagement of Canadian radiation ...
Matthew Beckett   +9 more
doaj   +1 more source

The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer

open access: yes, 2018
Our aim was to review the advances in radiation therapy for the management of pediatric cancers made by the Children's Oncology Group (COG) radiation oncology discipline since its inception in 2000.
John C. Breneman   +53 more
core   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

open access: yesAdvanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami   +7 more
wiley   +1 more source

DDX21 Enhances Radiosensitivity in Head and Neck Squamous Cell Carcinoma by Suppressing MK2‐Mediated DNA Damage Response

open access: yesAdvanced Science, EarlyView.
DDX21 suppresses MK2 activation by directly inhibiting Thr334 phosphorylation in a p38‐independent manner, thereby impairing DNA damage response. Clinically, patients with well‐differentiated tumors exhibiting high DDX21 expression are more likely to benefit from adjuvant radiotherapy, whereas those with low DDX21 levels are predisposed to ...
Tianru Yang   +8 more
wiley   +1 more source

American Society for Radiation Oncology's Advances in Radiation Oncology in 2022

open access: yesAdvances in Radiation Oncology, 2022
Miller, Robert C., Tsai, C. Jillian
openaire   +2 more sources

Home - About - Disclaimer - Privacy